Search
Lung Cancer Clinical Trials in Orlando, FL
A listing of 40 Lung Cancer clinical trials in Orlando, FL actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
25 - 36 of 40
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Lung Cancer
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
The city of Orlando, Florida, currently has 40 active clinical trials seeking participants for Lung Cancer research studies.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Recruiting
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Sara Cannon Research Institute Lake Nona, Orlando, Florida
Conditions: Non Small Cell Lung Cancer, Lung Cancer, Breast Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer, Head and Neck Squamous Cell Carcinoma
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
Recruiting
This is a multicenter, Phase 1/2 clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers. Module A will enroll participants with advanced/metastatic solid tumors. Additional modules exploring other cancers may be added to the master protocol at a later date. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: SCRI Florida Cancer Specialists, Orlando, Florida
Conditions: Advanced Solid Tumor, RAF Mutation, RAS Mutation, NF1 Mutation, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Melanoma, BRAF Gene Mutation, CRAF Gene Mutation, Castration-Resistant Prostate Cancer (CRPC)
Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
Recruiting
The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform across a basket of solid tumors, using in-vivo RECIST 1.1 as the reference method.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: AdventHealth Orlando, Orlando, Florida
Conditions: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Endometrial Cancer, Colorectal Cancer, Cutaneous Melanoma, Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Recruiting
Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: Local Institution - Unk055, Orlando, Florida
Conditions: Advanced NSCLC, Metastatic Lung Cancer
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Recruiting
This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2025
Locations: Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, Florida
Conditions: Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors, Solid Tumor, Pancreatic Adenocarcinoma, Advanced Solid Tumor
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Recruiting
This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, Florida
Conditions: Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors, Solid Tumor, Pancreatic Adenocarcinoma, Advanced Solid Tumor
Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas
Recruiting
This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas.
The main goals of this study are to:
* Find the recommended dose of IMT-009 that can be safely given to participants
* Learn more about the side effects of IMT-009
* Learn more about pharmacokinetics of IMT-009
* Learn more about the effectiveness of IMT-009
* Learn more about different pharmac... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Site 4100, Orlando, Florida
Conditions: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Small Bowel Cancer, Esophageal Cancer, Colorectal Cancer, Diffuse Large B Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Follicular Lymphoma
Real World Registry for Use of the Ion Endoluminal System
Recruiting
The primary objective of this study is to evaluate the performance of the Ion Endoluminal System with real-world use for pulmonary lesion localization or biopsy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Orlando Health Orlando Regional Medical Center, Orlando, Florida
Conditions: Lung Cancer, Multiple Pulmonary Nodules, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Diseases
A Study of PHN-010 in Patients with Advanced Solid Tumors
Recruiting
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-010, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: AdventHealth, Orlando, Florida
Conditions: Lung Cancer, Colon Cancer, Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Advanced Solid Tumor, Advanced Cancer
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Recruiting
This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/02/2025
Locations: Florida Cancer Specialists - Lake Nona, Orlando, Florida
Conditions: Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Recruiting
This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
12/04/2024
Locations: Orlando Health Cancer Institute, Orlando, Florida
Conditions: Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
Recruiting
The goal of this observational study is to learn how a physician uses the results of the Percepta® Nasal Swab test to manage people with a newly identified pulmonary nodule.
The main questions it aims to answer are:
* Does the use of the Percepta Nasal swab test reduce the number of invasive procedures in people with a low-risk result and whose nodule is benign?
* Does the use of the Percepta Nasal swab test decrease the time to treatment in people with a high-risk result and whose nodule is c... Read More
Gender:
ALL
Ages:
Between 29 years and 85 years
Trial Updated:
11/12/2024
Locations: Orlando VA Healthcare System, Orlando, Florida
Conditions: Pulmonary Nodule, Solitary, Lung Cancer
25 - 36 of 40